Table 1 Baseline and stress-induced cytokine levels (pg/ml) in the intervention and control conditions post treatment and at follow-up
From: Immune responses to stress after stress management training in patients with rheumatoid arthritis
| Ā | Ā | t= 0 minutes | t= 20 minutes | t= 40 minutes | t= 80 minutes |
|---|---|---|---|---|---|
IL-1Ī² | Ā | Ā | Ā | Ā | Ā |
āPost-treatment | IC | 92.39 (33.6) | 106.7 (41.4) | 111.3 (46.4) | 111.6 (45.4) |
| Ā | CC | 114.3 (38.6) | 130.9 (43.5) | 116.6 (37.0) | 136.7 (59.0) |
āFollow-up | IC | 66.48 (18.8) | 77.43 (23.7) | 69.49 (20.1) | 70.89 (19.9) |
| Ā | CC | 119.0 (43.0) | 100.7 (32.5) | 98.13 (34.1) | 117.6 (41.2) |
IL-2 | Ā | Ā | Ā | Ā | Ā |
āPost-treatment | IC | 28.11 (11.1) | 30.85 (11.9) | 34.83 (15.6) | 31.58 (13.4) |
| Ā | CC | 32.60 (14.0) | 42.86 (19.2) | 38.77 (17.3) | 47.51 (27.0) |
āFollow-up | IC | 20.28 (7.20) | 25.27 (10.3) | 17.37 (7.23) | 19.32 (7.15) |
| Ā | CC | 35.89 (18.4) | 27.82 (14.1) | 28.12 (14.0) | 32.24 (15.4) |
IL-4 | Ā | Ā | Ā | Ā | Ā |
āPost-treatment | IC | 48.22 (24.9) | 48.30 (21.0) | 48.98 (20.3) | 52.90 (25.7) |
| Ā | CC | 60.18 (29.3) | 72.79 (30.1) | 65.76 (28.4) | 65.39 (29.9) |
āFollow-up | IC | 33.22 (13.9) | 35.16 (14.9) | 33.62 (12.6) | 33.08 (13.6) |
| Ā | CC | 56.48 (23.2) | 51.79 (20.0) | 50.91 (21.5) | 56.99 (24.8) |
IL-5 | Ā | Ā | Ā | Ā | Ā |
āPost-treatment | IC | 20.94 (15.2) | 21.89 (15.3) | 23.24 (16.5) | 21.49 (15.6) |
| Ā | CC | 5.129 (2.17) | 7.887 (3.72) | 7.006 (2.94) | 8.948 (4.51) |
āFollow-up | IC | 16.23 (12.8) | 15.89 (12.1) | 15.14 (12.1) | 17.60 (14.5) |
| Ā | CC | 7.368 (3.48) | 6.048 (2.95) | 5.929 (2.60) | 6.969 (3.11) |
IL-6 | Ā | Ā | Ā | Ā | Ā |
āPost-treatment | IC | 36.46 (11.2) | 34.94 (9.69) | 38.80 (11.1) | 40.36 (11.2) |
| Ā | CC | 30.18 (9.36) | 41.18 (15.2) | 33.54 (10.7) | 39.57 (16.2) |
āFollow-up | IC | 25.79 (7.51) | 23.39 (7.90) | 23.63 (6.41) | 23.18 (6.68) |
| Ā | CC | 31.20 (14.1) | 30.18 (12.0) | 29.22 (11.3) | 30.43 (11.6) |
IL-7 | Ā | Ā | Ā | Ā | Ā |
āPost-treatment | IC | 70.11 (26.0) | 70.27 (24.8) | 73.62 (24.7) | 69.51 (27.2) |
| Ā | CC | 52.69 (16.5) | 63.65 (20.5) | 55.94 (18.5) | 60.73 (21.8) |
āFollow-up | IC | 52.54 (23.4) | 54.54 (23.5) | 49.13 (19.6) | 53.32 (22.2) |
| Ā | CC | 52.80 (18.4) | 53.69 (18.0) | 48.64 (18.2) | 52.89 (19.1) |
IL-8 | Ā | Ā | Ā | Ā | Ā |
āPost-treatment | IC | 22.14 (3.67) | 16.19 (3.70) | 17.02 (3.53) | 14.47 (3.41) |
| Ā | CC | 29.55 (6.50) | 34.04 (7.81) | 29.45 (6.75) | 28.18 (7.14) |
āFollow-up | IC | 19.51 (4.28) | 13.97 (4.67) | 12.53 (4.00) | 10.37 (3.38)a |
| Ā | CC | 33.63 (6.68) | 33.46 (8.33) | 29.31 (7.83) | 23.64 (5.72) |
IL-10 | Ā | Ā | Ā | Ā | Ā |
āPost-treatment | IC | 172.0 (75.2) | 183.7 (81.0) | 175.5 (80.0) | 164.7 (75.8) |
| Ā | CC | 49.33 (25.9) | 57.07 (31.8) | 73.55 (48.1) | 71.02 (45.9) |
āFollow-up | IC | 72.67 (35.6) | 115.6 (54.6) | 85.90 (41.9) | 78.49 (37.4) |
| Ā | CC | 46.83 (26.8) | 43.63 (24.2) | 39.90 (20.9) | 50.27 (28.0) |
IFNĪ³ | Ā | Ā | Ā | Ā | Ā |
āPost-treatment | IC | 1.063 (0.39) | 1.070 (0.43) | 0.821 (0.33) | 0.706 (0.31) |
| Ā | CC | 1.545 (0.45) | 8.328 (4.98) | 6.623 (4.91) | 7.591 (5.70) |
āFollow-up | IC | 0.857 (0.39) | 0.772 (0.32) | 0.925 (0.36) | 1.062 (0.38) |
| Ā | CC | 4.389 (2.87) | 8.535 (6.37) | 6.597 (4.98) | 7.377 (5,94) |
TNFĪ± | Ā | Ā | Ā | Ā | Ā |
āPost-treatment | IC | 31.40 (8.54) | 34.98 (8.95) | 34.82 (8.35) | 35.60 (10.7) |
| Ā | CC | 34.56 (12.4) | 39.35 (12.7) | 36.00 (11.1) | 35.45 (11.2) |
āFollow-up | IC | 23.90 (5.75) | 26.44 (6.94) | 24.74 (5.89) | 25.19 (6.44) |
| Ā | CC | 26.26 (8.74) | 23.84 (7.17) | 25.04 (9.44) | 25.93 (8.92) |